Cigarette smoking, appendectomy and tonsillectomy as risk factors for the development of primary sclerosing cholangitis (PSC): A case control study.

Cigarette smoking, appendectomy and tonsillectomy as risk factors for the development of primary sclerosing cholangitis (PSC): A case control study.

Dades bibliogràfiques
Autors principals:	Mitchell, SA, Thyssen, M, Mitchell, M, Orchard, T, Jewell, D, Fleming, K, Chapman, R
Format:	Journal article
Publicat:	1998

Ítems similars

Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.
per: Mitchell, SA, et al.
Publicat: (2002)

Cytokine profiles in primary sclerosing cholangitis (PSC) and autoimmune liver diseases: Comparing expression in the periphery and the liver.
per: Mitchell, SA, et al.
Publicat: (1997)

Primary sclerosing cholangitis.
per: Mitchell, SA, et al.
Publicat: (2000)

Enhanced cytokine mRNA expression in Primary Sclerosing Cholangitis (PSC) and autoimmune liver diseases.
per: Mitchell, S, et al.
Publicat: (1997)

ADHESION MOLECULE EXPRESSION IN PRIMARY SCLEROSING CHOLANGITIS (PSC)
per: Bloom, S, et al.
Publicat: (1992)

The management of primary sclerosing cholangitis.
per: Mitchell, SA, et al.
Publicat: (1998)

TISSUE DISTRIBUTION OF AN AUTOANTIGEN SPECIFIC FOR PRIMARY SCLEROSING CHOLANGITIS (PSC)
per: Lo, S, et al.
Publicat: (1992)

Deposition of complement C9 in primary sclerosing cholangitis (PSC).
per: Shanahan, J, et al.
Publicat: (1998)

IMMUNOGENETIC FACTORS IN THE CLINICAL COURSE OF PRIMARY SCLEROSING CHOLANGITIS (PSC)
per: Mehal, W, et al.
Publicat: (1993)

Down regulation of interferon gamma and up regulation of interleukin-10 by ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC).
per: Mitchell, SA, et al.
Publicat: (1997)

Role of interleukin-10 in the pathogenesis of primary sclerosing cholangitis and primary biliary cirrhosis?
per: Mitchell, SA, et al.
Publicat: (1998)

Review article: the management of primary sclerosing cholangitis.
per: Mitchell, SA, et al.
Publicat: (1997)

New time dependent prognostic models for primary sclerosing cholangitis (PSC)
per: Rocca, G, et al.
Publicat: (2000)

INAPPROPRIATE EXPRESSION OF BLOOD-GROUP ANTIGENS ON THE BILIARY EPITHELIUM IN PRIMARY SCLEROSING CHOLANGITIS (PSC)
per: Bloom, S, et al.
Publicat: (1990)

Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?
per: Chapman, R
Publicat: (2010)

Primary sclerosing cholangitis--an immunologically mediated disease?
per: Chapman, R, et al.
Publicat: (1985)

Liver cell proliferation in primary sclerosing cholangitis (PSC), as assessed by anti-KI-67 labelling.
per: Shanahan, J, et al.
Publicat: (1998)

PORTAL TRACT LYMPHOCYTE POPULATIONS IN PRIMARY SCLEROSING CHOLANGITIS
per: Snook, J, et al.
Publicat: (1987)

ANTINEUTROPHIL ANTIBODY AND PRIMARY SCLEROSING CHOLANGITIS
per: Lo, S, et al.
Publicat: (1991)

Primary sclerosing cholangitis
per: Chapman, R
Publicat: (2007)

Primary sclerosing cholangitis.
per: Chapman, R
Publicat: (1985)

High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial.
per: Mitchell, SA, et al.
Publicat: (1997)

Primary sclerosing cholangitis.
per: Cullen, S, et al.
Publicat: (2003)

A regulatory polymorphism of the stromelysin gene (MMP-3) strongly influences susceptibility to primary sclerosing cholangitis (PSC) and progression to portal hypertension.
per: Satsangi, J, et al.
Publicat: (2000)

Primary sclerosing cholangitis.
per: Williamson, K, et al.
Publicat: (2014)

Primary sclerosing cholangitis.
per: Worthington, J, et al.
Publicat: (2006)

Primary sclerosing cholangitis
per: Chapman Roger, et al.
Publicat: (2006-10-01)

Decreased interleukin-10 mRNA expression in primary sclerosing cholangitis and primary biliary cirrhosis: A role for IL10 in the pathogenesis?
per: Mitchell, SA, et al.
Publicat: (1997)

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
per: Mitchell, SA, et al.
Publicat: (2001)

Characterization of the antigen for the antineutrophil cytoplasmic antibody specific for primary sclerosing cholangitis (PSC) ulcerative colitis (UC).
per: Cameron, B, et al.
Publicat: (1998)

OLIGONUCLEOTIDE DNA TYPING ANALYSIS OF THE HLA DRB3 LOCUS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)
per: Mehal, W, et al.
Publicat: (1991)

INTERFERON-GAMMA PRODUCTION IN PRIMARY SCLEROSING CHOLANGITIS
per: Martins, E, et al.
Publicat: (1995)

ANTI-NEUTROPHIL NUCLEAR ANTIBODY IN INFLAMMATORY BOWEL-DISEASE AND PRIMARY SCLEROSING CHOLANGITIS
per: Snook, J, et al.
Publicat: (1988)

Is the 308 polymorphism in the tumor necrosis factor (alpha) (TNF alpha) promoter region a marker of disease susceptibility in European patients with primary sclerosing cholangitis (PSC)?
per: Mitchell, SA, et al.
Publicat: (1998)

The management of primary sclerosing cholangitis.
per: Chapman, R
Publicat: (2003)

The immunology of primary sclerosing cholangitis.
per: Chapman, R
Publicat: (1990)

Primary sclerosing cholangitis - Foreword
per: Chapman, R
Publicat: (2006)

THE IMMUNOGENETICS OF PRIMARY SCLEROSING CHOLANGITIS
per: Chapman, R
Publicat: (1993)

High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial.
per: Mitchell, S, et al.
Publicat: (1997)

Tissue distribution of autoantigen specific for primary sclerosing cholangitis.
per: Lo, S, et al.
Publicat: (1993)